Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has, since the company’s inception, been driven by the development of a network of point-of-care (“POC”) analyzers that run on its HealthTab(TM) software in community pharmacies, workplaces and rural areas. Earlier this year, the company signed a deal with Abbott to expand the distribution of its Affinion 2 analyzers in pharmacies. Shortly thereafter, Avricore also entered an agreement with Shoppers Drug Mart to stock HealthTab for diabetes screening in 11 different locations. “The company has recognized an opportunity and capitalizes on established consumer trends, technology advancements, health policy and industry changes to solve a business headache while also meeting a significant market opportunity. All this is built on the company’s HealthTab platform,” reads a recent article. “So far, HealthTab can check up to 27 health markers, screen diabetes and conduct rapid Covid-19 testing. It also offers convenience, with analyses taking less than 10 minutes…. The milestones achieved with HealthTab so far are significant. More so, they highlight the endless possibilities that the platform has regarding the diagnosis of various chronic diseases, bacteria and viruses.”
To view the full article, visit https://ibn.fm/7pkpk
About Avricore Health Inc.
Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab(TM), (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. For more information about the company, visit www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
